NYSE$AMRX
Amneal Pharmaceuticals Inc · Q3 2024 earnings
Q3 2024 earnings · · Investor relations
Briefing
AMRX Q3 2024 — $702K revenue
Investors should realize that if underlying assumptions prove inaccurate, known or unknown risks or uncertainties materialize, or other factors or circumstances change, our actual results and financia. Amneal Pharmaceuticals Inc reported Q3 2024 results. Net income of $12K. Headline numbers extracted from the Form 10-Q press release; narrative is light because this row was processed without an LLM call.
- Revenue: $702K.
- Net income: $12K.
- Operating income: $89K.
- Gross profit: $270K.
Headline financials
Revenue & EPS history
Amneal · Revenue · Quarterly
$702M
Revenue by segment
Amneal · $620M total across 3 segments · Q3 2023
- Affordable Medicines$391M+11.6%63.0%
- AvKARE$132M+24.6%21.3%
- Specialty$97.3M+8.7%15.7%
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q3 2024
-0.6%
Avg return
Earnings day
-3.2%
Avg return
5 days after
+0.4%
Avg return
30 days after
54%
20 / 37 earnings
Positive
+36.6%
Q2 2023
Best reaction
-23.0%
Q3 2019
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | +0.7% | -7.6% | +0.9% | |
| Q4 2025 | -4.6% | -8.2% | -18.2% | |
| Q3 2025 | -4.1% | +8.8% | +20.0% | |
| Q1 2025 | +3.0% | -6.7% | -5.4% | |
| Q4 2024 | +3.5% | +7.0% | -1.2% | |
| Q3 2024 | +6.9% | +4.9% | -1.9% | |
| Q2 2024 | +12.9% | +9.6% | +21.9% | |
| Q1 2024 | +7.1% | +6.1% | +7.6% | |
| Q4 2023 | -2.2% | -3.8% | +9.8% | |
| Q3 2023 | -3.6% | +0.2% | +11.4% | |
| Q2 2023 | +36.6% | +25.9% | +25.6% | |
| Q1 2023 | +9.8% | -3.3% | +38.6% | |
| Q4 2022 | -8.1% | -15.8% | -33.5% | |
| Q3 2022 | +13.0% | +8.2% | +16.8% | |
| Q2 2022 | -9.5% | -9.2% | -36.4% | |
| Q1 2022 | -11.5% | -22.2% | -13.0% | |
| Q4 2021 | -7.0% | -12.4% | -3.4% | |
| Q3 2021 | -12.5% | -9.8% | -29.0% | |
| Q2 2021 | +4.5% | +4.9% | +6.6% | |
| Q1 2021 | -8.1% | -8.0% | -5.5% | |
| Q4 2020 | +5.9% | +0.0% | +40.1% | |
| Q3 2020 | -15.0% | -15.6% | -14.6% | |
| Q2 2020 | -16.3% | -19.9% | -30.7% | |
| Q1 2020 | +20.3% | +16.1% | +42.5% | |
| Q4 2019 | -20.4% | -16.4% | -37.0% | |
| Q3 2019 | -23.0% | -23.0% | +7.0% | |
| Q2 2019 | -8.0% | -10.5% | -18.5% | |
| Q1 2019 | -20.7% | -31.0% | -41.8% | |
| Q4 2018 | +8.4% | +2.0% | +13.8% | |
| Q3 2018 | +5.1% | +4.6% | -9.1% | |
| Q2 2018 | +0.6% | +9.8% | +19.4% | |
| Q1 2018 | +1.5% | +13.3% | +30.2% | |
| Q4 2017 | +4.4% | — | — | |
| Q3 2017 | +5.9% | — | — | |
| Q2 2017 | +1.5% | — | — | |
| Q1 2017 | -3.2% | — | — | |
| Q4 2016 | +2.3% | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro